the 2021 annual report was released on Zhejiang Starry Pharmaceutical Co.Ltd(603520) 25, and the company achieved an operating revenue of 1999916900 yuan, a year-on-year increase of 46.29%; The net profit attributable to the shareholders of the listed company was 323754800 yuan, a year-on-year increase of 35.62%; After deducting non operating profits and losses, the net profit attributable to shareholders of the listed company was 307864100 yuan, a year-on-year increase of 30.04%.
With the pilot of DRG / dip, the implementation of medical insurance negotiation policy, comprehensive clinical evaluation of drugs and a series of policies aimed at promoting cost-effective drug use have been gradually implemented, which has a profound impact on the industry pattern Zhejiang Starry Pharmaceutical Co.Ltd(603520) is a high-tech enterprise specializing in the R & D, production and sales of pharmaceutical characteristic APIs. After more than 20 years of development, the company has become the largest and most complete manufacturer of contrast agent raw materials in China.
Zhejiang Starry Pharmaceutical Co.Ltd(603520) has five R & D centers including Zhejiang Starry Pharmaceutical Co.Ltd(603520) Zhejiang Research Institute of non-ionic contrast agents, Zhejiang Zhejiang Starry Pharmaceutical Co.Ltd(603520) Institute of diagnostic drugs (provincial enterprise research institute) and the Department of pharmaceutical regulations. Around the research and development of CT / NMR / contrast-enhanced ultrasound / preparations / intermediates and other products, more than 30 authorized invention patents have been obtained. The company has established postdoctoral workstations in Zhejiang and Jiangxi, and actively carried out technical cooperation with Zhejiang University, Xiamen University, Shanghai Institute of pharmacy, Chinese Academy of Sciences and other universities and institutes. During the reporting period, the company completed the submission of supplementary materials for iodomepur injection and iodofol injection and accepted on-site inspection. In December 2021, the registration application for gadolinium besmeglumine injection was submitted to CDE. By the end of the reporting period, the company and its subsidiaries have granted and are reviewing a total of 69 patents, including 49 invention patents, 17 utility models and 3 design patents.
In terms of main products, Zhejiang Starry Pharmaceutical Co.Ltd(603520) the production capacity and output of iohexol API rank first in China, and the production capacity of iohexol and ioxamol API rank first in China. The products declared by the subsidiary Shanghai Zhejiang Starry Pharmaceutical Co.Ltd(603520) Pharmaceutical Co., Ltd., such as iodophor injection, iohexol injection and iodixanol injection, are the first to pass the national new class 4 Registration (deemed to pass the “drug consistency evaluation”). The company is at the leading level in the field of impurity separation and synthesis of levofloxacin series products in China. It is one of the largest levofloxacin series manufacturers in China. “Si Beiqing” and others have established high public awareness, the company’s product quality is stable, and has obtained certification from many developed countries.
Zhejiang Starry Pharmaceutical Co.Ltd(603520) is extended by the characteristic API business and has formed a unique advantage in the cdmo field related to iodine chemistry. At the same time, the company has been deeply engaged in Levofloxacin series products for many years, and has produced and sold levofloxacin APIs and intermediates. Based on the competitive advantage in the field of characteristic APIs and the massive customer resources accumulated in recent 20 years, the company continues to layout the CMO / cdmo business of APIs and intermediates, opening a new growth pole for the development of the company.
On February 1, 2021, the centralized procurement of the first batch of drugs in Shandong Province began, and Zhejiang Starry Pharmaceutical Co.Ltd(603520) of iohexol injection and ioxamol injection were selected in the centralized procurement of Shandong Province. On June 28, 2021, the company’s iohexol injection and ioxamol injection were selected, and the fifth batch of drugs were purchased centrally across the country, which was implemented nationwide in October 2021. During the reporting period, the company established and improved the company’s sales network in all provinces of the country with the help of the successful selection of centralized procurement in Shandong Province and national centralized procurement, and established a professional academic team for promotion, so as to officially enter the preparation industry of contrast agent in the field of imaging.
During the reporting period, Zhejiang Starry Pharmaceutical Co.Ltd(603520) continued to steadily promote the industrial layout of “intermediate API preparation” integration, improve the company’s advantages in product quality, production cost and supply chain connection, and strengthen the toughness of the industrial chain; Shanghai iodine contrast agent all link linkage intelligent transformation project has entered the electromechanical installation stage. Jiangxi and Haishen raised and invested intermediate and API projects have completed plant construction and entered the electromechanical installation and trial production stage. The four industrial bases give full play to their respective advantages and cooperate closely.
